Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05192200 · ClinicalTrials.gov registry record · Phase 2
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
A Phase 2 study of Dermatomyositis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 20
- Study locations
NCT05192200 is a Phase 2 study of Dermatomyositis that has completed, run by Pfizer. The registered enrollment target is 24 participants, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05192200, a Phase 2 study of Dermatomyositis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
Conditions Studied
Interventions
- DRUG Anti-Beta Interferon (PF-06823859)
Study Locations (20)
New York
- NYU Grossman School of Medicine, The Ronald O. Perelman Department of Dermatology - New York
- NYU Langone Health Clinical Research Center - New York
- NYU Langone Radiology - Ambulatory Care Center East 41st Street - New York
- Mount Sinai Doctors Dermatology - New York
- Icahn School of Medicine at Mount Sinai - New York
Kansas
- KU Clinical Research Center - Clinical and Translational Science Unit (CTSU) - Fairway
- KU Clinical and Translational Science Unit (CTSU) Rainbow - Kansas City
- University of Kansas Medical Center - Kansas City
Missouri
- Center for Outpatient Health - St Louis
- Washington University School of Medicine - St Louis
- Washington University School of Medicine - St Louis
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham, Department of Dermatology - Birmingham
Massachusetts
- Brigham & Women's Hospital - Boston
- Brigham and Women's Hospital - CTH - Boston
Arizona
- Mayo Clinic - Scottsdale
California
- Attune Health Research Inc. - Beverly Hills
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05192200
The ClinicalTrials.gov registry entry for NCT05192200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (95% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatomyositis appearing as the primary indexed condition, and to 1 intervention - of which Anti-Beta Interferon (PF-06823859) is the first listed.
NCT05192200 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New York, Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT05192200 about?
NCT05192200 is a clinical study titled "An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study". The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
What is the current status of trial NCT05192200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-12-20. Estimated completion is 2023-11-20.
What conditions does trial NCT05192200 study?
This clinical trial studies the following conditions: Dermatomyositis.
What interventions are being tested in trial NCT05192200?
The interventions under investigation include: Anti-Beta Interferon (PF-06823859) (DRUG).
Who is sponsoring clinical trial NCT05192200?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05192200 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
RECRUITING · Phase 2
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
-
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.